CDBIO(688739)2022-04-14 16:00Financial Performance - The company achieved a net profit attributable to shareholders of the parent company of ¥892,490,658.44 in 2021, with a total profit available for distribution to shareholders of ¥892,229,814.14 after statutory surplus reserve allocation[8]. - A cash dividend of ¥10 per 10 shares (including tax) is proposed, totaling ¥416,450,000, which accounts for 46.66% of the net profit attributable to shareholders of the parent company for 2021[8]. - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 15%[26]. - The company achieved operating revenue of CNY 2,088,043,469.78 in 2021, representing a year-on-year increase of 4.63%[33]. - The net profit attributable to shareholders was CNY 892,490,658.44, a decrease of 2.80% compared to the previous year[37]. - The net profit after deducting non-recurring gains and losses was CNY 862,518,502.00, reflecting a year-on-year increase of 2.13%[37]. - The net cash flow from operating activities was CNY 506,376,172.18, down 41.09% year-on-year, primarily due to delayed customer payments caused by the COVID-19 pandemic[37]. - The company's total assets reached CNY 9,792,731,456.06 at the end of 2021, an increase of 118.67% compared to the end of 2020[38]. - The net assets attributable to shareholders increased to CNY 9,352,015,548.09, marking a growth of 127.09% year-on-year[38]. - Basic earnings per share decreased by 4.49% to CNY 2.34 in 2021[36]. Research and Development - The R&D expenditure accounted for 14.91% of operating revenue, an increase of 3.77 percentage points compared to the previous year[36]. - The company has established three major R&D technology platforms, with over 20 vaccine varieties currently under research, including innovative and multi-valent vaccines[66]. - The company’s total R&D investment for the year reached ¥311,399,620.91, representing a year-on-year increase of 40.04% and accounting for 14.91% of the company's operating revenue[112][113]. - The company filed 17 new intellectual property applications during the reporting period, including 9 invention patent applications, and received 3 patent grants[111]. - The number of R&D personnel increased to 170, up from 155 in the previous year, with R&D personnel accounting for 11.12% of the total workforce[121]. - The company is currently conducting clinical trials for several vaccines, including the quadrivalent influenza vaccine, which is in Phase III trials with a total investment of ¥29,800,000[117]. - The company is actively expanding its R&D efforts, with a focus on new product development and clinical trials for various vaccines[113][117]. - The company has established three distinct technology platforms for vaccine development: bacterial vaccines, viral vaccines, and multi-valent vaccines, aligning with industry trends[102]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[26]. - The company has completed the acquisition of a local biotech firm, which is expected to enhance its R&D capabilities and product pipeline[26]. - The company is enhancing its management system post-listing, focusing on risk prevention and talent recruitment to support future development[62]. - The company is committed to increasing R&D investment to mitigate long-term technology iteration risks and ensure the leading position of its core technology[129]. - The company is focusing on expanding its product portfolio to reduce risks associated with a relatively single product structure, particularly in rabies and encephalitis vaccines[135]. Operational Challenges and Risks - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[12]. - The company has not violated decision-making procedures for external guarantees[12]. - The company has not faced any issues with more than half of the directors being unable to ensure the authenticity, accuracy, and completeness of the annual report[12]. - The company is closely monitoring macroeconomic conditions to manage investment risks effectively[145]. - The company faces potential foreign exchange risks due to international sales and purchases, which could impact financial performance[148]. - The company is increasing R&D investments to address the risk of declining demand for human rabies vaccines in the long term[149]. Product Development and Innovation - The company is currently developing a new mRNA vaccine, expected to enter clinical trials by Q3 2022[26]. - The approval for clinical trials of the 15-valent HPV vaccine was received in December 2021, marking a significant breakthrough in innovative vaccine projects[53]. - The company is advancing the development of new technologies and processes for its existing vaccines, including the human rabies vaccine and the human Japanese encephalitis vaccine[66]. - The company’s innovative approaches in vaccine technology, such as the use of VLP technology, are expected to improve the safety and efficacy of its vaccine products[106]. Sales and Marketing - User data indicates that the company has expanded its customer base by 20% in the last year, reaching a total of 5 million active users[26]. - The company has a strong domestic sales team of nearly 300 professionals, covering all provinces and regions in China, and an international sales network in over 30 countries[128]. - The company is enhancing its marketing network and expanding its sales team to improve market penetration and brand recognition[139]. - The company has established strict management protocols for third-party promotional agencies and overseas distributors to mitigate risks[140]. Audit and Compliance - The company has received a standard unqualified audit opinion from Rongcheng Accounting Firm[7]. - The company has not reported any special arrangements for corporate governance[9].